These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10938510)

  • 41. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
    Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
    Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors predicting interferon treatment response in patients with chronic hepatitis c: late viral clearance does not preclude a sustained response.
    Ebeling F; Lappalainen M; Vuoristo M; Nuutinen H; Leino R; Karvonen AL; Lehtola J; Julkunen R; Pohjanpelto P; Färkkilä M
    Am J Gastroenterol; 2001 Apr; 96(4):1237-42. PubMed ID: 11316176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study.
    Grant PR; Black A; Garcia N; Prieto J; Garson JA
    J Med Virol; 2000 Aug; 61(4):439-42. PubMed ID: 10897061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
    Lau DT; Kleiner DE; Ghany MG; Park Y; Schmid P; Hoofnagle JH
    Hepatology; 1998 Oct; 28(4):1121-7. PubMed ID: 9755252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low virological response to interferon in children with chronic hepatitis C.
    Pensati P; Iorio R; Botta S; Tuccillo C; Donetto S; Vajro P; Ciarlo G; Vegnente A
    J Hepatol; 1999 Oct; 31(4):604-11. PubMed ID: 10551382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients.
    Ozdemir FN; Akcay A; Sezer S; Boyacioglu S; Ozdemir BH; Arat Z; Haberal M
    Ren Fail; 2004 Sep; 26(5):583-8. PubMed ID: 15526919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.
    Hanrotel C; Toupance O; Lavaud S; Thiefin G; Brodard V; Ingrand D; Diebold MD; Wynckel A; Chanard J
    Nephron; 2001 Jun; 88(2):120-6. PubMed ID: 11399913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C? Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Kato N; Yoshida H; Imazeki F; Okano K; Yokosuka O; Omata M
    J Gastroenterol Hepatol; 1999 Jan; 14(1):79-84. PubMed ID: 10029282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of patients with chronic hepatitis C and normal ALT levels.
    Tassopoulos NC
    J Hepatol; 1999; 31 Suppl 1():193-6. PubMed ID: 10622586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
    Naveau S; Balian A; Degos F; Daurat V; Chevret S; Gayno S; Bastie A; Riachi G; Bartolomei-Portal I; Barange K; Moussalli J; Bailly F; Chaumet-Riffaud P; Emilie D
    J Hepatol; 1999 Oct; 31(4):612-7. PubMed ID: 10551383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels.
    Ohmiya M; Hayashi J; Ueno K; Furusyo N; Sawayama Y; Kawakami Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 2000 Oct; 45(10):1953-8. PubMed ID: 11117566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.
    Toccaceli F; Laghi V; Capurso L; Koch M; Sereno S; Scuderi M;
    J Viral Hepat; 2003 Mar; 10(2):126-33. PubMed ID: 12614469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity.
    Tran A; Longo F; Ouzan D; Bianchi D; Pradier C; Saint-Paul MC; Sattonnet C; Laffont C; Dantin S; Piche T; Benzaken S; Rampal P
    Scand J Gastroenterol; 2000 Apr; 35(4):433-7. PubMed ID: 10831269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of chronic hepatitis C with interferon-alpha by monitoring the response according to viraemia.
    Bonetti P; Chemello L; Antona C; Breda A; Brosolo P; Casarin P; Crivellàro C; Donà G; Martinelli S; Rinaldi R; Zennaro V; Santonastaso M; Urban F; Pontisso P; Alberti A
    J Viral Hepat; 1997 Mar; 4(2):107-12. PubMed ID: 9097266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic changes in hypervariable region 1 as a possible mechanism for biochemical responders with interferon therapy.
    Shindo M; Hamada K; Oda Y; Okuno T
    Liver; 2002 Apr; 22(2):184-5. PubMed ID: 12028415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.